[go: up one dir, main page]

AR103406A1 - Sal de tosilato - Google Patents

Sal de tosilato

Info

Publication number
AR103406A1
AR103406A1 ARP160100076A ARP160100076A AR103406A1 AR 103406 A1 AR103406 A1 AR 103406A1 AR P160100076 A ARP160100076 A AR P160100076A AR P160100076 A ARP160100076 A AR P160100076A AR 103406 A1 AR103406 A1 AR 103406A1
Authority
AR
Argentina
Prior art keywords
salt
tosilate
tetrahydropyrrolo
fluoropyrimidin
thiazin
Prior art date
Application number
ARP160100076A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR103406A1 publication Critical patent/AR103406A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente se refiere a una sal de tosilato de N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropirimidin-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamida. Composiciones farmacéuticas. Reivindicación 1: Un compuesto caracterizado porque es una sal de tosilato de N-[3-[(4aR,7aS)-2-amino-6-(5-fluoropirimidin-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-metoxi-pirazina-2-carboxamida.
ARP160100076A 2015-01-30 2016-01-13 Sal de tosilato AR103406A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562109733P 2015-01-30 2015-01-30

Publications (1)

Publication Number Publication Date
AR103406A1 true AR103406A1 (es) 2017-05-10

Family

ID=55275232

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160100076A AR103406A1 (es) 2015-01-30 2016-01-13 Sal de tosilato

Country Status (41)

Country Link
US (1) US10080758B2 (es)
EP (1) EP3250575B1 (es)
JP (2) JP6723250B2 (es)
KR (1) KR101950129B1 (es)
CN (1) CN107108657B (es)
AR (1) AR103406A1 (es)
AU (1) AU2016211827B2 (es)
BR (1) BR112017012149A2 (es)
CA (1) CA2969475C (es)
CL (1) CL2017001899A1 (es)
CO (1) CO2017007810A2 (es)
CR (1) CR20170287A (es)
CY (1) CY1122548T1 (es)
DK (1) DK3250575T3 (es)
DO (1) DOP2017000159A (es)
EA (1) EA031330B1 (es)
EC (1) ECSP17048768A (es)
ES (1) ES2768782T3 (es)
GT (1) GT201700166A (es)
HR (1) HRP20192240T1 (es)
HU (1) HUE048029T2 (es)
IL (1) IL252754A0 (es)
LT (1) LT3250575T (es)
MA (1) MA41420B1 (es)
MD (1) MD3250575T2 (es)
ME (1) ME03581B (es)
MX (1) MX2017009713A (es)
NZ (1) NZ732381A (es)
PE (1) PE20171333A1 (es)
PH (1) PH12017501356A1 (es)
PL (1) PL3250575T3 (es)
PT (1) PT3250575T (es)
RS (1) RS59730B1 (es)
SG (1) SG11201706038PA (es)
SI (1) SI3250575T1 (es)
SV (1) SV2017005478A (es)
TN (1) TN2017000332A1 (es)
TW (1) TWI574969B (es)
UA (1) UA119581C2 (es)
WO (1) WO2016122968A1 (es)
ZA (1) ZA201703937B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT401651B (de) * 1994-06-14 1996-11-25 Biochemie Gmbh 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4-
CN101939306A (zh) * 2007-12-07 2011-01-05 美国辉瑞有限公司 反式-n-异丁基-3-氟-3-[3-氟-4-(吡咯烷-1-基-甲基)-苯基]环丁烷甲酰胺的甲苯磺酸盐
SI2233474T1 (sl) * 2008-01-18 2015-11-30 Eisai R&D Management Co., Ltd. Kondenziran derivat aminodihidrotiazina
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
TWI570127B (zh) * 2014-09-15 2017-02-11 美國禮來大藥廠 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物
AR103406A1 (es) * 2015-01-30 2017-05-10 Lilly Co Eli Sal de tosilato

Also Published As

Publication number Publication date
MX2017009713A (es) 2017-11-17
PH12017501356A1 (en) 2017-12-11
MA41420B1 (fr) 2020-02-28
BR112017012149A2 (pt) 2018-01-02
EP3250575A1 (en) 2017-12-06
SV2017005478A (es) 2018-02-09
SI3250575T1 (sl) 2019-12-31
US10080758B2 (en) 2018-09-25
KR101950129B1 (ko) 2019-02-19
GT201700166A (es) 2018-11-23
EA031330B1 (ru) 2018-12-28
IL252754A0 (en) 2017-08-31
CY1122548T1 (el) 2021-01-27
CN107108657A (zh) 2017-08-29
WO2016122968A1 (en) 2016-08-04
HRP20192240T1 (hr) 2020-03-06
HUE048029T2 (hu) 2020-05-28
TW201636354A (zh) 2016-10-16
US20170368071A1 (en) 2017-12-28
JP6723250B2 (ja) 2020-07-15
CO2017007810A2 (es) 2017-10-20
PL3250575T3 (pl) 2020-06-01
DK3250575T3 (da) 2020-01-20
PE20171333A1 (es) 2017-09-13
ME03581B (me) 2020-07-20
KR20170097782A (ko) 2017-08-28
CA2969475A1 (en) 2016-08-04
AU2016211827A1 (en) 2017-06-22
NZ732381A (en) 2018-05-25
ES2768782T3 (es) 2020-06-23
TN2017000332A1 (en) 2019-01-16
CR20170287A (es) 2017-07-20
JP2019142902A (ja) 2019-08-29
ECSP17048768A (es) 2017-11-30
CN107108657B (zh) 2021-10-08
CA2969475C (en) 2019-06-18
JP2018503666A (ja) 2018-02-08
EA201791229A1 (ru) 2017-11-30
MD3250575T2 (ro) 2020-03-31
ZA201703937B (en) 2019-01-30
AU2016211827B2 (en) 2018-04-26
DOP2017000159A (es) 2017-07-31
TWI574969B (zh) 2017-03-21
LT3250575T (lt) 2020-02-10
RS59730B1 (sr) 2020-02-28
EP3250575B1 (en) 2019-11-20
UA119581C2 (uk) 2019-07-10
SG11201706038PA (en) 2017-08-30
CL2017001899A1 (es) 2018-03-23
PT3250575T (pt) 2020-01-16

Similar Documents

Publication Publication Date Title
CL2018001488A1 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
MA47123A (fr) Dérivés de benzooxazole en tant qu'mmunomodulateurs
BR112017025398A2 (pt) formas de dosagem sólidas de palbociclib
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EP3377065A4 (en) SPIROCYCLIC PYRIDOTRIAZINE DERIVATIVES FOR USE AS HIV INTEGRASE INHIBITORS
EA201790672A1 (ru) Композиция, содержащая соль ацилглутамата в качестве основного поверхностно-активного вещества или основного анионного поверхностно-активного вещества
EP3328379A4 (en) BIS-HETEROARYL DERIVATIVES AS MODULATORS OF THE PROTEIN AGGREGATION
EP3504185A4 (en) NEW SUBSTITUTED N'-HYDROXYCARBAMIMIDOYL-1,2,5-OXADIAZOLE COMPOUNDS AS INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE (IDO)
MA41041A (fr) Dérivés de benzothiazole substitués utilisés en tant qu'agonistes de gpr40 pour le traitement du diabète de type ii
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
MA41542A (fr) Nouveaux dérivés de n-acyl-arylsulfonamide utilisés en tant qu'inhibiteurs d'aminoacyl-arnt synthétase
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201691983A1 (ru) Пиридин-2-амиды, пригодные в качестве агонистов cb2
AR095097A1 (es) Compuestos de fenoxietoxi
EP2953470A4 (en) 2,6,7-SUBSTITUTED PURINS AS HDM2 INHIBITORS
MA41174A (fr) Dérivés d'imidazopyridazine utilisés en tant qu'inhibiteurs de pi3kbeta
EA201992168A1 (ru) Аналоги деутетрабеназина, их получение и применение
AR103406A1 (es) Sal de tosilato
MX382659B (es) Proceso para la preparación de derivados de tiazol.
CO2017010725A2 (es) N-[3-[(4as,5s,7as)-2-amino-5-(1,1-difluoroetil)-4,4a,5,7-tetrahidrofuro[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-ciano-2-picolamida, su sal metanosulfonato y una forma cristalina hemihidrato de la sal 4-metilbencenosulfonato del mismo, composiciones que los contienen y procedimientos para su elaboración
AR098614A1 (es) Compuesto para el tratamiento de hipoglicemia severa
CO2017001927A2 (es) Formas cristalinas de n-[3-[(4ar,7as)-2-amino-6-(5- fluoropirimidin-2-il)-4,4a,5,7-tetrahidropirrolo[3,4-d][1,3]tiazin-7a-il]-4-fluoro-fenil]-5-metoxi-pirazin-2-carboxamida como inhibidores de bace
DOP2017000016A (es) Nueva sal de disoproxilo de tenofovir
HK1241377A1 (en) Tosylate salt of n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluoro-phenyl]-5-methoxy-pyrazine-2-carboxamide
ГЕПАТИТА et al. 112∎ MATERIALS OF CONFERENCES∎

Legal Events

Date Code Title Description
FB Suspension of granting procedure